

Neurodevelopmental Assessments to Screen for HIV Encephalopathy in Newly Diagnosed Infants not on ART in Mozambique

Jyodi Mohole¹, Silvia Chauque², Helton Zucula³, Luisa Lambo², Anselmo Lisboa², Domitila Ferreira³, Harshika Chowdhary¹, Belinda Kande³, Beatriz Elias², Amir Seni³, W. Chris Buck, MD^{1,2}

¹David Geffen School of Medicine at UCLA, ²Hospital Central de Maputo ³Hospital Central de Beira



Background

- Encephalopathy represents a common and serious manifestation of pediatric HIV infection. Approximately **18%** of HIV-infected children have HIV-associated encephalopathy (HIVE).¹
- HIVE has not been extensively described in infected infants less than 12 months of age.²
- Children with HIVE have worse outcomes, including increased morbidity and mortality.³

Aims

- Describe the baseline clinical and demographic profile of a cohort of HIV-infected infants diagnosed during hospital admission and not yet on ART.
- Assess their neurodevelopmental clinical presentation
- Determine the prevalence of presumptive HIVE
- Determine clinical and demographic variables associated with HIVE

Methods


- Retrospectively analyzed routine, standard of care hospitalization data from the Lactentes wards at Hospital Central de Maputo (HCM) and Hospital Central de Beira (HCB)
 - Both sites have point-of-care DNA PCR for timely, definitive infant HIV diagnosis
- Criteria for inclusion:**
 - HIV-infected children aged <12 months
 - not currently on ART
 - admitted between Jan 1, 2019 - June 30, 2019
- Assessments of development were made using WHO Integrated Management of Childhood Illness (IMCI) milestone tables⁴
- WHO Criteria for HIVE Diagnosis**⁵
 - One of the following clinical events progressing over at least two months in the absence of another illness:
 - failure to attain, or loss of developmental milestones, OR
 - progressive impaired brain growth demonstrated by stagnation of head circumference, OR
 - acquired symmetrical motor deficit accompanied by two or more of the following: paresis, pathological reflexes, ataxia and gait disturbance
 - These criteria were adapted for a **presumptive HIVE** diagnosis for this inpatient study without post-discharge follow-up
- Statistical analyses were performed in Excel® and SPSS®

References

1. Hilburn, N., Potterton, J. & Stewart, A. Paediatric HIV encephalopathy in sub-Saharan Africa. *Phys. Ther. Rev.* **15**, 410–417 (2010).
2. Donald, K. A. *et al.* HIV Encephalopathy: Pediatric case series description and insights from the clinic coalface. *AIDS Res. Ther.* **12**, 2 (2015).
3. Lobato, M. N., Caldwell, M. B., Ng, P. & Oxtoby, M. J. Encephalopathy in children with perinatally acquired human immunodeficiency virus infection. *J. Pediatr.* **126**, 710–715 (1995).
4. World Health Organization. "Integrated Management of Childhood Illness: Distance Learning Course." (2014)
5. World Health Organization. "WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children." (2007): 37.


Results

- A total of **31 patients** were included in the study.
- Mean age was **5 months**, with **15 females and 16 males**.
- Pneumonia/ Bronchopneumonia/ Bronchiolitis (26%)** and **Sepsis (19%)** were the most common primary hospitalization diagnoses.
- Respiratory illnesses accounted for approximately **50%** of the diagnoses.
- 8 patients** were diagnosed with presumptive HIVE. These patients had delayed or lost milestones as well as microcephaly or pathological reflexes



	(+) HIVE (n=8)	(-) HIVE (n=20)	P-value
Sex			
Male	6 (75%)	9 (43%)	.22
Female	2 (25%)	11 (55%)	
Age at Admission			
< 2 months	0 (0%)	2 (10%)	.18
2 - 4 months	4 (50%)	4 (20%)	
4 - 6 months	3 (38%)	6 (30%)	
6 - 9 months	0 (0%)	7 (35%)	
9 - 12 months	1 (12%)	1 (5%)	
Prior Hospitalization			
Yes	3 (38%)	4 (20%)	.37
No	5 (62%)	16 (80%)	
Maternal HIV Diagnosis			
Pre-Pregnancy	1 (12%)	3 (15%)	.035
Pregnancy	2 (25%)	14 (75%)	
Post-Partum	5 (63%)	3 (15%)	
Maternal ART Start			
Pre-Pregnancy	0 (0%)	3 (15%)	.007
Pregnancy	2 (25%)	14 (70%)	
Post-Partum	1 (12%)	1 (5%)	
None	5 (63%)	2 (10%)	
Postnatal Prophylaxis			
NVP	2 (25%)	16 (80%)	.011
None	6 (75%)	4 (20%)	
Previous (-) PCR			
Yes	0 (0%)	5 (25%)	.49
No	8 (100%)	15 (75%)	

- Delayed milestones were seen in **70% patients** included
- HIVE(+) were, on average, delayed in **2.75** categories vs **1.21** in the HIVE (-) group.
- The prevalence of delayed milestones was approximately **2x higher** in the HIVE(+) group across all milestone categories.



Limitations

- Lack of serial assessments – presumptive HIVE diagnosis
- No CD4 reagents for immunologic assessments
- Baseline viral load testing not part of Mozambique guidelines
- Data collection at HCB were interrupted by Cyclone Idai

Conclusions

- HIVE prevalence is high in newly diagnosed infants (**28.5%**), particularly in those with risk factors for in-utero transmission
- Infants with HIVE need comprehensive care that includes ART and physical/occupational therapy where available